Alzheimer's Dementia

Both Abstinence and High Alcohol Use Linked to Dementia

August 14, 2018

Among those drinking more than 14 units/week, there was a 17% increase in dementia risk with a 7-unit increase in alcohol consumption.

Monoclonal Antibody Granted Orphan Drug Status for Frontotemporal Dementia

By August 09, 2018

There are currently no treatments available for frontotemporal dementia.

No Higher Risk of Autoimmune Disorders After HPV4 Vaccination

July 30, 2018

No significant risks were seen in exploratory analyses of individual autoimmune disorders, including Bell's palsy, optic neuritis, and Graves' disease.

Positive Phase 2 Results for Novel Alzheimer Disease Treatment BAN2401

By July 27, 2018

Initial data from Study 201, as announced in December 2017, showed BAN2401 did not meet the primary endpoint.

Certain Statins May Be Associated With Deficits in Cognition, Memory

By July 26, 2018

Given the lack of differences seen via the NIS, the authors suggested that subjective questionnaires may not be a trustworthy method to assess possible statin-associated cognitive deficits.

Diclofenac May Slow Cognitive Decline in Alzheimer Disease

July 25, 2018

Study results showed that most common NSAIDs, including aspirin, ibuprofen, naproxen, and celecoxib did not alter cognitive degeneration in patients with mild cognitive impairment or Alzheimer disease.

Treatment for Alzheimer-Related Agitation Gets Fast Track Status

By July 16, 2018

Currently, there are no approved treatments for behavioral symptoms (eg, aggression, agitation) in Alzheimer's disease.

Blister Packs for Several Meds Recalled Due to Risk of Harm to Children

By July 09, 2018

The recall affects approximately 470,000 units that include drugs packaged with 3 to 10 tablets per blister card. The blister packs were developed for use in hospitals, however some were sent to retail pharmacies and were likely dispensed for in-home use.

Trials for Investigational Alzheimer's Tx Lanabecestat Discontinued

By June 12, 2018

The independent data monitoring committee (IDMC) concluded that the 2 trials (AMARANTH and DAYBREAK-ALZ) investigating the treatment in mild Alzheimer's disease dementia, were not likely to meet their primary endpoints of change from baseline on the 13-item Alzheimer's Disease Assessment Scale - Cognitive Subscale.

Better Dietary Patterns Among US Adults Could Save Billions

June 11, 2018

Cost savings were estimated at $66.9 and $135 billion, respectively, if the diet quality of US adults were to improve to achieve 80% of the maximum healthy eating index 2015 and mediterranean diet scores.

Intellectual Activities in Later Life May Cut Dementia Risk

June 07, 2018

After those who developed dementia within 3 years after baseline were excluded and after adjustment for health behaviors, physical and psychiatric comorbidities, and sociodemographic factors, the estimated odds ratio for incident dementia was 0.71 for those with intellectual activities at baseline.

Studies Halted for Alzheimer's Candidate Atabecestat Due to Safety Concerns

By May 23, 2018

Janssen said in a statement that they are informing study participants (N>600), trial investigators, health authorities, ethics committees and institutional review boards about the situation.

Aerobic + Strength Exercise Doesn't Slow Cognitive Decline

May 17, 2018

The researchers found that the mean Alzheimer's disease assessment scale-cognitive subscale score had increased to 25.2 and 23.8 in the exercise arm and usual care group, respectively, by 12 months (adjusted between-group difference, −1.4), indicating greater cognitive impairment in the exercise group

Surgical repair improves survival, pain control in patients with dementia who suffer hip fracture

May 15, 2018

In this retrospective study, nursing home patients with dementia who had a hip fracture had improved survival if they underwent surgical repair compared to non-surgical management.

Primary Care Providers Have Mixed Views on Genetic Tests

May 14, 2018

They find tests for genetic risk potentially useful, but lack confidence in interpreting results

Treating Apathy in Alzheimer's Disease Patients: A Meta-Analysis

By May 11, 2018

Methylphenidate demonstrated an improvement in apathy vs placebo when measured by the apathy evaluation scale, in addition, methylphenidate showed possible improvement in cognition.

Tips on Improving Communication With Older Patients

By May 10, 2018

Communication with older patients can be complicated for several reasons.

Women Have Stronger Link With Alzheimer's Gene, <i>APOE</i>-&#949;4

May 09, 2018

"Sex difference in the association with neurofibrillary tangles at autopsy suggest that APOE may modulate risk for neurodegeneration in a sex-specific manner, particularly in the presence of amyloidosis," the authors write.

Mild TBI Linked to Increased Dementia Risk in Veterans

May 08, 2018

The researchers observed small differences between veterans with and without TBI. Overall, 2.6 and 6.1% of those without and with TBI, respectively, developed dementia.

Anticholinergic Drug Use and Dementia: What's the Link?

By April 26, 2018

A total of 14,453 (35%) cases and 86,403 (30%) controls were prescribed at least 1 anticholingeric drug with an Anticholinergic Cognitive Burden (ACB) score of 3; 1429 (3.5%) cases and 7909 (2.8%) controls were prescribed drugs with an ACB score of 2; most patients (89% of cases and 87% of controls) received a drug with an ACB score of 1 during the drug exposure period (DEP).

Untrimmed Toenails: A Marker of Functional Status in Older Patients?

By April 13, 2018

For older patients, toenail length can provide important insight into a patient's functional status.

Phase 3 Results Released for Investigational Alzheimer's Disease Treatment

By April 10, 2018

Results showed that after 18-months, there was no significant statistical difference in cognitive or functional outcomes between those patients taking azeliragon and the placebo group.

One Night of Sleep Deprivation Linked to Amyloid-&#946; Burden

April 10, 2018

These increases were associated with mood worsening after sleep deprivation; however, they were not associated with the genetic risk for Alzheimer's disease (APOE genotype).

apoE Aggregation May Impact apoE-Mediated Plaque Formation

April 03, 2018

"These data support the hypothesis that a primary mechanism for apoE-mediated plaque formation may be a result of apoE aggregation, as preferentially targeting of apoE aggregates with therapeutic antibodies reduces Aβ pathology and may represent a selective approach to treat Alzheimer's disease," the authors write.

Can Long-Term PPI Use Increase Hip Fracture Risk in Alzheimer's?

March 22, 2018

The researchers found that long-term or cumulative proton pump inhibitor use was not associated with an increased risk of hip fracture.

Excessive Daytime Sleepiness Linked to β-Amyloid Accumulation in Elderly

March 13, 2018

The researchers found that baseline EDS, defined as an Epworth Sleepiness Scale score of at least 10, was significantly correlated with increased regional Aβ accumulation in the anterior cingulate, posterior cingulate-precuneus, and parietal regions.

Pimavanserin Evaluated in Patients With Alzheimer's Disease Psychosis

February 15, 2018

By week 12, for the overall population there was no significant advantage for pimavanserin versus placebo (treatment difference, −0.51; 95% CI, −2.23 to 1.21; P=0.561). Common adverse events in both groups included falls, urinary tract infections, and agitation.

Study Evaluating Verubecestat in Prodromal Alzheimer's Disease Stopped

By February 14, 2018

APECS is a randomized, placebo-controlled, parallel-group, double-blind Phase 3 clinical trial evaluating the efficacy and safety of verubecestat in people with prodromal AD.

BACE1 Inhibition May Hold Key to Preventing Alzheimer's

February 14, 2018

"Our results demonstrate that sustained and increasing BACE1 inhibition in adults can reverse amyloid deposition in an AD mouse model, and this observation will help to provide guidance for the proper use of BACE1 inhibitors in human patients," the authors write.

Circadian Dysfunction May Serve as Early Alzheimer's Biomarker

January 31, 2018

"The presence of circadian rhythm abnormalities in the preclinical phase of AD suggests that circadian dysfunction could contribute to early disease pathogenesis or serve as a biomarker of preclinical disease," the authors write.